Polarization of Tumor Cells and Tumor-Associated Macrophages: Molecular Mechanisms and Therapeutic Targets

Abstract

Tumor-associated macrophages (TAMs) are prominent constituents of solid tumors, and their prevalence is often associated with poor clinical outcomes. These highly adaptable immune cells undergo dynamic functional changes within the immunosuppressive tumor microenvironment (TME), engaging in reciprocal interactions with malignant cells. This bidirectional communication facilitates concurrent phenotypic transformation: tumor cells shift toward invasive mesenchymal states, whereas TAMs develop immunosuppressive, pro-tumorigenic traits. Increasing evidence highlights metabolic reprogramming, characterized by dysregulation of lipid metabolism, amino acid utilization, and glycolytic activity, as the fundamental molecular basis orchestrating this pathological symbiosis. However, a comprehensive understanding of how metabolic reprogramming specifically coordinates the mutual polarization of tumor cells and TAMs is lacking. This review thoroughly examines the molecular mechanisms governing this co-polarization process, detailing critical transcriptional regulators, essential signaling pathways, and the maintenance of adaptive phenotypes within the TME. Furthermore, this review critically assesses promising therapeutic strategies aimed at disrupting this alliance, including the use of metabolically targeted agents, engineered chimeric antigen receptor macrophages, and TAM-selective nanoparticle delivery systems. These insights provide a crucial foundation for the development of next-generation cancer immunotherapies focused on reprogramming pathological polarization dynamics to overcome treatment resistance and improve clinical outcomes.

Keywords

metabolism reprogramming / TAMs / TME / tumor cell

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229-263.

[2] H. Ma, Z. Kang, T. K. Foo, et al., “Disrupted BRCA1‒PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in HCC Through cGAS‒STING Pathway,” Hepatology 77, no. 1 (2023): 33-47.

[3] M. Alonso-Nocelo, L. Ruiz-Cañas, P. Sancho, et al., “Macrophages Direct Cancer Cells Through a LOXL2-Mediated Metastatic Cascade in Pancreatic Ductal Adenocarcinoma,” Gut 72, no. 2 (2023): 345-359.

[4] M. A. Martin-Serrano, B. Kepecs, and M. Torres-Martin, “Novel Microenvironment-Based Classification of Intrahepatic Cholangiocarcinoma With Therapeutic Implications,” Gut 72, no. 4 (2023): 736-748.

[5] F. Anagnostakis and C. Piperi, “Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas,” Current Neuropharmacology 21, no. 3 (2023): 457-470.

[6] A. N. Chamseddine, T. Assi, O. Mir, et al., “Modulating Tumor-Associated Macrophages to Enhance the Efficacy of Immune Checkpoint Inhibitors: A TAM-pting Approach,” Pharmacology & Therapeutics 231 (2022): 107986.

[7] X. Zhou, Q. Liu, X. Wang, et al., “Exosomal ncRNAs Facilitate Interactive ‘Dialogue’ Between Tumor Cells and Tumor-Associated Macrophages,” Cancer Letters 552 (2023): 215975.

[8] L. Shu, X. Li, Z. Liu, et al., “Bile Exosomal miR-182/183-5p Increases Cholangiocarcinoma Stemness and Progression by Targeting HPGD and Increasing PGE2 Generation,” Hepatology 79, no. 2 (2024): 307-322.

[9] E. Hirooka, R. Hattori, K. Ikawa, et al., “Macrophages Promote Tumor Growth by Phagocytosis-mediated Cytokine Amplification in Drosophila,” Current Biology 35, no. 13 (2025): 3209-3227.

[10] Y. Niu, J. Chen, and Y. Qiao, “Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe,” Frontiers in Immunology 13 (2022): 836223.

[11] J. Wu, X. Wang, L. Chen, et al., “Oxygen Microcapsules Improve Immune Checkpoint Blockade by Ameliorating Hypoxia Condition in Pancreatic Ductal Adenocarcinoma,” Bioactive Materials 20 (2023): 259-270.

[12] C. Zhang, S. Wei, S. Dai, et al., “The NR_109/FUBP1/c-Myc Axis Regulates TAM Polarization and Remodels the Tumor Microenvironment to Promote Cancer Development,” Journal for ImmunoTherapy of Cancer 11, no. 5 (2023): e006230.

[13] M. Bied, W. W. Ho, F. Ginhoux, et al., “Roles of Macrophages in Tumor Development: A Spatiotemporal Perspective,” Cellular & Molecular Immunology 20, no. 9 (2023): 983-992.

[14] M. T. Patterson, A. L. Burrack, Y. Xu, et al., “Tumor-Specific CD4 T Cells Instruct Monocyte Fate in Pancreatic Ductal Adenocarcinoma,” Cell Reports 42, no. 7 (2023): 112732.

[15] A. Vogel and T. Weichhart, “Tissue-Resident Macrophages—Early Passengers or Drivers in the Tumor Niche?” Current Opinion in Biotechnology 83 (2023): 102984.

[16] H. Zhang, Q. Zheng, T. Guo, et al., “Metabolic Reprogramming in Astrocytes Results in Neuronal Dysfunction in Intellectual Disability,” Molecular Psychiatry 29, no. 6 (2024): 1569-1582.

[17] I. Peñuelas-Haro, R. Espinosa-Sotelo, E. Crosas-Molist, et al., “The NADPH Oxidase NOX4 Regulates Redox and Metabolic Homeostasis Preventing HCC Progression,” Hepatology 78, no. 2 (2023): 416-433.

[18] K. Mortezaee and J. Majidpoor, “Dysregulated Metabolism: A Friend-to-Foe Skewer of Macrophages,” International Reviews of Immunology 42, no. 4 (2023): 287-303.

[19] S. Hussain, S. Tulsyan, S. A. Dar, et al., “Role of Epigenetics in Carcinogenesis: Recent Advancements in Anticancer Therapy,” Seminars in Cancer Biology 83 (2022): 441-451.

[20] X. Yue, Y. Kong, Y. Zhang, et al., “SREBF2‒STARD4 Axis Confers Sorafenib Resistance in Hepatocellular Carcinoma by Regulating Mitochondrial Cholesterol Homeostasis,” Cancer Science 114, no. 2 (2023): 477-489.

[21] P. Jayaprakash, P. D. A. Vignali, G. M. Delgoffe, et al., “Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy,” Annual Review of Medicine 73 (2022): 251-265.

[22] D. Samovski, M. Jacome-Sosa, and N. A. Abumrad, “Fatty Acid Transport and Signaling: Mechanisms and Physiological Implications,” Annual Review of Physiology 85 (2023): 317-337.

[23] D. F. Quail, M. Park, A. L. Welm, et al., “Breast Cancer Immunity: It is TIME for the Next Chapter,” Cold Spring Harbor Perspectives in Medicine 14, no. 2 (2024): a041324.

[24] K. Jandl, N. Radic, K. Zeder, et al., “Pulmonary Vascular Fibrosis in Pulmonary Hypertension—The Role of the Extracellular Matrix as a Therapeutic Target,” Pharmacology & Therapeutics 247 (2023): 108438.

[25] C. Q. Chu and T. Quan, “Fibroblast Yap/Taz Signaling in Extracellular Matrix Homeostasis and Tissue Fibrosis,” Journal of Clinical Medicine 13, no. 12 (2024): 3358.

[26] S. Rastogi, S. Aldosary, A. S. Saeedan, et al., “NF-κB Mediated Regulation of Tumor Cell Proliferation in Hypoxic Microenvironment,” Frontiers in Pharmacology 14 (2023): 1108915.

[27] A. Yamaguchi, Y. Mukai, T. Sakuma, et al., “Monocarboxylate Transporter 4 Involves in Energy Metabolism and Drug Sensitivity in Hypoxia,” Scientific Reports 13, no. 1 (2023): 1501.

[28] J. Wei, G. Lei, Q. Chen, et al., “Casticin Inhibits Proliferation of Non-Small Cell Lung Cancer Cells Through Regulating Reprogramming of Glucose Metabolism,” Phytomedicine 136 (2025): 156278.

[29] Q. Y. Chen, B. Gao, D. Tong, et al., “Crosstalk Between Extracellular Vesicles and Tumor-Associated Macrophage in the Tumor Microenvironment,” Cancer Letters 552 (2023): 215979.

[30] B. R. Ford, P. D. A. Vignali, N. L. Rittenhouse, et al., “Tumor Microenvironmental Signals Reshape Chromatin Landscapes to Limit the Functional Potential of Exhausted T Cells,” Science Immunology 7, no. 74 (2022): eabj9123.

[31] P. D. A. Vignali, K. Depeaux, M. J. Watson, et al., “Hypoxia Drives CD39-Dependent Suppressor Function in Exhausted T Cells to Limit Antitumor Immunity,” Nature Immunology 24, no. 2 (2023): 267-279.

[32] X. Zhou, H. Chen, Y. Shi, et al., “Histone Deacetylase 8 Inhibition Prevents the Progression of Peritoneal Fibrosis by Counteracting the Epithelial‒Mesenchymal Transition and Blockade of M2 Macrophage Polarization,” Frontiers in Immunology 14 (2023): 1137332.

[33] Y. Zhao, C. Xing, Y. Deng, et al., “HIF-1α Signaling: Essential Roles in Tumorigenesis and Implications in Targeted Therapies,” Genes & Diseases 11, no. 1 (2024): 234-251.

[34] S. Zhi, C. Chen, H. Huang, et al., “Hypoxia-inducible Factor in Breast Cancer: Role and Target for Breast Cancer Treatment,” Frontiers in Immunology 15 (2024): 1370800.

[35] A. Varveri, M. Papadopoulou, Z. Papadovasilakis, et al., “Immunological Synapse Formation Between T Regulatory Cells and Cancer-Associated Fibroblasts Promotes Tumour Development,” Nature Communications 15, no. 1 (2024): 4988.

[36] S. Chen, W. Cui, Z. Chi, et al., “Tumor-Associated Macrophages Are Shaped by Intratumoral High Potassium via Kir2.1,” Cell Metabolism 34, no. 11 (2022): 1843-1859. e1811.

[37] U. Al-Sheikh and L. Kang, “Kir2.1 Channel: Macrophage Plasticity in Tumor Microenvironment,” Cell Metabolism 34, no. 11 (2022): 1613-1615.

[38] C. Gao, J. Li, and B. Shan, “Research Progress on the Regulatory Role of Lactate and Lactylation in Tumor Microenvironment,” Biochimica Biophysica Acta: Reviews on Cancer 1880, no. 3 (2025): 189339.

[39] S. Chen, Y. Xu, W. Zhuo, et al., “The Emerging Role of Lactate in Tumor Microenvironment and Its Clinical Relevance,” Cancer Letters 590 (2024): 216837.

[40] S. Xu, O. Chaudhary, P. Rodríguez-Morales, et al., “Uptake of Oxidized Lipids by the Scavenger Receptor CD36 Promotes Lipid Peroxidation and Dysfunction in CD8(+) T Cells in Tumors,” Immunity 54, no. 7 (2021): 1561-1577. e1567.

[41] S. S. Pillai, D. G. Pereira, J. Zhang, et al., “Contribution of Adipocyte Na/K-ATPase α1/CD36 Signaling Induced Exosome Secretion in Response to Oxidized LDL,” Frontiers in Cardiovascular Medicine 10 (2023): 1046495.

[42] Y. Chen, M. Yang, W. Huang, et al., “Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses,” Circulation Research 125, no. 12 (2019): 1087-1102.

[43] L. Arpinati and R. Scherz-Shouval, “From Gatekeepers to Providers: Regulation of Immune Functions by Cancer-Associated Fibroblasts,” Trends in Cancer 9, no. 5 (2023): 421-443.

[44] B. Toledo, L. Zhu Chen, M. Paniagua-Sancho, et al., “Deciphering the Performance of Macrophages in Tumour Microenvironment: A Call for Precision Immunotherapy,” Journal of Hematology & Oncology 17, no. 1 (2024): 44.

[45] Y. Zhang, F. Zhong, and L. Liu, “Single-Cell Transcriptional Atlas of Tumor-Associated Macrophages in Breast Cancer,” Breast Cancer Research 26, no. 1 (2024): 129.

[46] R. Fontana, A. Mestre-Farrera, and J. Yang, “Update on Epithelial‒Mesenchymal Plasticity in Cancer Progression,” Annual Review of Pathology 19 (2024): 133-156.

[47] X. Zhang, Y. Zhang, C. Wang, et al., “TET (Ten-Eleven Translocation) Family Proteins: Structure, Biological Functions and Applications,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 297.

[48] K. Jabbari, A. Khalafizadeh, M. Sheikhbahaei, et al., “TET1: The Epigenetic Architect of Clinical Disease Progression,” Genes & Diseases 12, no. 5 (2025): 101513.

[49] M. Liao, D. Yao, L. Wu, et al., “Targeting the Warburg Effect: A Revisited Perspective From Molecular Mechanisms to Traditional and Innovative Therapeutic Strategies in Cancer,” Acta Pharmaceutica Sinica B 14, no. 3 (2024): 953-1008.

[50] A. F. Karimova, A. R. Khalitova, R. Suezov, et al., “Immunometabolism of Tumor-Associated Macrophages: A Therapeutic Perspective,” European Journal of Cancer 220 (2025): 115332.

[51] Y. Shao, S. Han, Z. Hou, et al., “Tumor-Associated Macrophages Within the Immunological Milieu: An Emerging Focal Point for Therapeutic Intervention,” Heliyon 10, no. 17 (2024): e36839.

[52] X. Yang, B. Deng, W. Zhao, et al., “FABP5(+) Lipid-Loaded Macrophages Process Tumour-Derived Unsaturated Fatty Acid Signal to Suppress T-Cell Antitumour Immunity,” Journal of Hepatology 82, no. 4 (2025): 676-689.

[53] L. Cassetta and J. W. Pollard, “A Timeline of Tumour-Associated Macrophage Biology,” Nature Reviews Cancer 23, no. 4 (2023): 238-257.

[54] J. Xiang, J. Wang, H. Xiao, et al., “Targeting Tumor-Associated Macrophages in Colon Cancer: Mechanisms and Therapeutic Strategies,” Frontiers in Immunology 16 (2025): 1573917.

[55] X. Peng and J. Du, “Histone and Non-Histone Lactylation: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets,” Molecular Biomedicine 6, no. 1 (2025): 38.

[56] L. Zhao, H. Qi, H. Lv, et al., “Lactylation in Health and Disease: Physiological or Pathological?,” Theranostics 15, no. 5 (2025): 1787-1821.

[57] K. Xu, K. Zhang, Y. Wang, et al., “Comprehensive Review of Histone Lactylation: Structure, Function, and Therapeutic Targets,” Biochemical Pharmacology 225 (2024): 116331.

[58] Z. Yang, Y. X. Wang, J. K. Wen, et al., “SF3B4 Promotes Twist1 Expression and Clear Cell Renal Cell Carcinoma Progression by Facilitating the Export of KLF 16 mRNA From the Nucleus to the Cytoplasm,” Cell Death & Disease 14, no. 1 (2023): 26.

[59] J. J. F. Sleeboom, S. Van Tienderen G, K. Schenke-Layland, et al., “The Extracellular Matrix as Hallmark of Cancer and Metastasis: From Biomechanics to Therapeutic Targets,” Science Translational Medicine 16, no. 728 (2024): eadg3840.

[60] C. Liu, J. Qiang, Q. Deng, et al., “ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression,” Cancer Research 81, no. 23 (2021): 5919-5934.

[61] S. Dhar, T. Sarkar, S. Bose, et al., “FOXP3 Transcriptionally Activates Fatty Acid Scavenger Receptor CD36 in Tumour-Induced Treg Cells,” Immunology 174, no. 3 (2025): 296-309.

[62] T. Guan, M. Li, Y. Song, et al., “Phosphorylation of USP29 by CDK1 Governs TWIST1 Stability and Oncogenic Functions,” Advanced Science (Weinheim) 10, no. 11 (2023): e2205873.

[63] J. Sun, E. Esplugues, A. Bort, et al., “Fatty Acid Binding Protein 5 Suppression Attenuates Obesity-Induced Hepatocellular Carcinoma by Promoting Ferroptosis and Intratumoral Immune Rewiring,” Nature Metabolism 6, no. 4 (2024): 741-763.

[64] W. George Warren, M. Osborn, A. Yates, et al., “The Emerging Role of Fatty Acid Binding Protein 5 (FABP5) in Cancers,” Drug Discovery Today 28, no. 7 (2023): 103628.

[65] H. Chen, X. Zhang, Z. Wang, et al., “Activated Kynurenine Pathway Metabolism by YKL-40 Establishes an Inhibitory Immune Microenvironment and Drives Glioblastoma Development,” Cellular and Molecular Life Sciences 82, no. 1 (2024): 11.

[66] M. R. Jennings, D. Munn, and J. Blazeck, “Immunosuppressive Metabolites in Tumoral Immune Evasion: Redundancies, Clinical Efforts, and Pathways Forward,” Journal for ImmunoTherapy of Cancer 9, no. 10 (2021): e003013.

[67] C. Yao, S. Wu, J. Kong, et al., “Angiogenesis in Hepatocellular Carcinoma: Mechanisms and Anti-Angiogenic Therapies,” Cancer Biology & Medicine 20, no. 1 (2023): 25-43.

[68] T. Xiang, F. Sun, T. Liu, et al., “EBV-associated Epithelial Cancers Cells Promote Vasculogenic Mimicry Formation via a Secretory Cross-Talk With the Immune Microenvironment,” Theranostics 14, no. 13 (2024): 5123-5140.

[69] C. Haymaker, D. H. Johnson, R. Murthy, et al., “Tilsotolimod With Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma,” Cancer Discovery 11, no. 8 (2021): 1996-2013.

[70] J. Zhou, L. Liu, X. Hu, et al., “Matrix Metalloproteinase-21 Promotes Metastasis via Increasing the Recruitment and M2 Polarization of Macrophages in HCC,” Cancer Science 114, no. 2 (2023): 423-435.

[71] G. Marelli, N. Morina, F. Portale, et al., “Lipid-Loaded Macrophages as New Therapeutic Target in Cancer,” Journal for ImmunoTherapy of Cancer 10, no. 7 (2022): e004584.

[72] D. K. Ahirwar, B. Peng, M. Charan, et al., “Slit2/Robo1 Signaling Inhibits Small-Cell Lung Cancer by Targeting β-Catenin signaling in Tumor Cells and Macrophages,” Molecular Oncology 17, no. 5 (2023): 839-856.

[73] C. Zong, Y. Meng, F. Ye, et al., “AIF1 + CSF1R + MSCs, Induced by TNF-α, Act to Generate an Inflammatory Microenvironment and Promote Hepatocarcinogenesis,” Hepatology 78, no. 2 (2023): 434-451.

[74] Y. Zhu, A. Wang, S. Zhang, et al., “Paclitaxel-Loaded Ginsenoside Rg3 Liposomes for Drug-Resistant Cancer Therapy by Dual Targeting of the Tumor Microenvironment and Cancer Cells,” Journal of Advanced Research 49 (2023): 159-173.

[75] H. T. Nguyen, E. L. Kan, M. Humayun, et al., “Patient-specific Vascularized Tumor Model: Blocking Monocyte Recruitment With Multispecific Antibodies Targeting CCR2 and CSF-1R,” Biomaterials 312 (2025): 122731.

[76] Y. Liu, T. Fu, G. Li, et al., “Mitochondrial Transfer Between Cell Crosstalk—An Emerging Role in Mitochondrial Quality Control,” Ageing Research Reviews 91 (2023): 102038.

[77] Y. Yin, B. Liu, Y. Cao, et al., “Colorectal Cancer-Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD-L1 Expression in Tumor-Associated Macrophages,” Advanced Science (Weinheim) 9, no. 9 (2022): 2102620.

[78] H. Lian, M. Yu, Q. Li, et al., “Hypoxic Breast Cancer Cell-Derived Exosomal miR-143-3p Targets RICTOR to Regulate M2 Macrophage Polarization, Thereby Modulating Cancer Cell Invasiveness,” Human Cell 38, no. 4 (2025): 114.

[79] X. Li, Q. Guo, Q. Chen, et al., “Reconciling the Cooperative-Competitive Patterns Among Tumor and Immune Cells for Triple-Negative Breast Cancer Treatment Using Multimodule Nanocomplexes,” Advanced Materials 36, no. 26 (2024): e2312219.

[80] K. Yang, T. Yang, J. Yu, et al., “Integrated Transcriptional Analysis Reveals Macrophage Heterogeneity and Macrophage‒Tumor Cell Interactions in the Progression of Pancreatic Ductal Adenocarcinoma,” BMC Cancer 23, no. 1 (2023): 199.

[81] S. Wang, J. T. Shi, X. R. Wang, et al., “1H-Indazoles Derivatives Targeting PI3K/AKT/mTOR Pathway: Synthesis, Anti-Tumor Effect and Molecular Mechanism,” Bioorganic Chemistry 133 (2023): 106412.

[82] T. H. Hung, Y. Huang, C. T. Yeh, et al., “High Expression of Embryonic Stem Cell Marker SSEA3 Confers Poor Prognosis and Promotes Epithelial Mesenchymal Transition in Hepatocellular Carcinoma,” Biomedical Journal 47, no. 2 (2024): 100612.

[83] X. Zhang, M. Zhang, H. Sun, et al., “The Role of Transcription Factors in the Crosstalk Between Cancer-Associated Fibroblasts and Tumor Cells,” Journal of Advanced Research 67 (2025): 121-132.

[84] Z. Chen, J. Lu, X. M. Zhao, et al., “Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models,” Advanced Sciences (Weinheim) 11, no. 41 (2024): e2404854.

[85] H. Ikeda, K. Kawase, T. Nishi, et al., “Immune Evasion Through Mitochondrial Transfer in the Tumour Microenvironment,” Nature 638, no. 8049 (2025): 225-236.

[86] K. M. Tharp, K. Kersten, O. Maller, et al., “Tumor-Associated Macrophages Restrict CD8(+) T Cell Function Through Collagen Deposition and Metabolic Reprogramming of the Breast Cancer Microenvironment,” Nature Cancer 5, no. 7 (2024): 1045-1062.

[87] O. Maller, A. P. Drain, A. S. Barrett, et al., “Tumour-Associated Macrophages Drive Stromal Cell-Dependent Collagen Crosslinking and Stiffening to Promote Breast Cancer Aggression,” Nature Materials 20, no. 4 (2021): 548-559.

[88] Y. Wang, R. Narasimamurthy, M. Qu, et al., “Circadian Regulation of Cancer Stem Cells and the Tumor Microenvironment During Metastasis,” Nature Cancer 5, no. 4 (2024): 546-556.

[89] R. Jin, L. Neufeld, and T. L. McGaha, “Linking Macrophage Metabolism to Function in the Tumor Microenvironment,” Nature Cancer 6, no. 2 (2025): 239-252.

[90] S. B. Lacher, J. Dörr, and P. De Almeida G, “PGE(2) Limits Effector Expansion of Tumour-Infiltrating Stem-Like CD8(+) T Cells,” Nature 629, no. 8011 (2024): 417-425.

[91] X. Wang, S. Su, Y. Zhu, et al., “Metabolic Reprogramming via ACOD1 Depletion Enhances Function of Human Induced Pluripotent Stem Cell-Derived CAR-Macrophages in Solid Tumors,” Nature Communications 14, no. 1 (2023): 5778.

[92] L. Wu, X. Zhang, L. Zheng, et al., “RIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis,” Cancer Immunology Research 8, no. 5 (2020): 710-721.

[93] D. Li, T. Zhang, Y. Guo, et al., “Biological Impact and Therapeutic Implication of Tumor-Associated Macrophages in Hepatocellular Carcinoma,” Cell Death & Disease 15, no. 7 (2024): 498.

[94] S. Sun, G. Qi, H. Chen, et al., “Ferroptosis Sensitization in Glioma: Exploring the Regulatory Mechanism of SOAT1 and Its Therapeutic Implications,” Cell Death & Disease 14, no. 11 (2023): 754.

[95] F. Su and A. Koeberle, “Regulation and Targeting of SREBP-1 in Hepatocellular Carcinoma,” Cancer and Metastasis Reviews 43, no. 2 (2024): 673-708.

[96] S. Zhang, T. Fang, Y. He, et al., “VHL Mutation Drives Human Clear Cell Renal Cell Carcinoma Progression Through PI3K/AKT-Dependent Cholesteryl Ester Accumulation,” EBioMedicine 103 (2024): 105070.

[97] K. C. Kao, S. Vilbois, and C. H. Tsai, “Metabolic Communication in the Tumour-Immune Microenvironment,” Nature Cell Biology 24, no. 11 (2022): 1574-1583.

[98] X. Song, G. Liu, Y. Bin, et al., “C1q/Tumor Necrosis Factor-Related Protein-9 Enhances Macrophage Cholesterol Efflux and Improves Reverse Cholesterol Transport via AMPK Activation,” Biochemical Genetics 63, no. 2 (2025): 1620-1634.

[99] A. Nicolini and P. Ferrari, “Involvement of Tumor Immune Microenvironment Metabolic Reprogramming in Colorectal Cancer Progression, Immune Escape, and Response to Immunotherapy,” Frontiers in Immunology 15 (2024): 1353787.

[100] B. Zhang, Y. Zhu, Y. Tang, et al., “The Mediator Subunit Complex Protein MED15 Promotes Lipid Deposition and Cancer Progression During Hypoxia,” Journal of Biological Chemistry 301, no. 3 (2025): 108296.

[101] X. T. Liu, Y. Huang, D. Liu, et al., “Targeting the SphK1/S1P/PFKFB3 Axis Suppresses Hepatocellular Carcinoma Progression by Disrupting Glycolytic Energy Supply That Drives Tumor Angiogenesis,” Journal of Translational Medicine 22, no. 1 (2024): 43.

[102] M. Mazzoni, G. Mauro, M. Erreni, et al., “Senescent Thyrocytes and Thyroid Tumor Cells Induce M2-Like Macrophage Polarization of Human Monocytes via a PGE2-Dependent Mechanism,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 208.

[103] G. Li, X. Che, and S. Wang, “The Role of Cisplatin in Modulating the Tumor Immune Microenvironment and Its Combination Therapy Strategies: A New Approach to Enhance Anti-Tumor Efficacy,” Annals of Medicine 57, no. 1 (2025): 2447403.

[104] M. Morotti, A. J. Grimm, H. C. Hope, et al., “PGE(2) Inhibits TIL Expansion by Disrupting IL-2 Signalling and Mitochondrial Function,” Nature 629, no. 8011 (2024): 426-434.

[105] R. Y. Ma, A. Black, and B. Z. Qian, “Macrophage Diversity in Cancer Revisited in the Era of Single-Cell Omics,” Trends in Immunology 43, no. 7 (2022): 546-563.

[106] L. Beer, V. Bura, S. Ursprung, et al., “Assessment of Early Response to Neoadjuvant Chemotherapy in Multi-Site High-Grade Serous Ovarian Cancer Using Hyperpolarized-(13)C MRI,” EJNMMI Research 15, no. 1 (2025): 40.

[107] E. Kazakova, P. Iamshchikov, I. Larionova, et al., “Macrophage Scavenger Receptors: Tumor Support and Tumor Inhibition,” Frontiers in Oncology 12 (2022): 1096897.

[108] N. Caronni, F. La Terza, F. M. Vittoria, et al., “IL-1β(+) Macrophages Fuel Pathogenic Inflammation in Pancreatic Cancer,” Nature 623, no. 7986 (2023): 415-422.

[109] R. Dietze, M. K. Hammoud, M. Gomez-Serrano, et al., “Phosphoproteomics Identify Arachidonic-Acid-Regulated Signal Transduction Pathways Modulating Macrophage Functions With Implications for Ovarian Cancer,” Theranostics 11, no. 3 (2021): 1377-1395.

[110] A. J. Ozga, M. T. Chow, and A. D. Luster, “Chemokines and the Immune Response to Cancer,” Immunity 54, no. 5 (2021): 859-874.

[111] C. Castillo, M. Grieco, and S. D'amone, “Hypoxia Effects on Glioblastoma Progression Through YAP/TAZ Pathway Regulation,” Cancer Letters 588 (2024): 216792.

[112] Y. T. Wang, A. J. Trzeciak, W. S. Rojas, et al., “Metabolic Adaptation Supports Enhanced Macrophage Efferocytosis in Limited-Oxygen Environments,” Cell Metabolism 35, no. 2 (2023): 316-331. e316.

[113] L. Wang, C. Zhang, J. Zhao, et al., “Biomimetic Targeting Nanoadjuvants for Sonodynamic and Chronological Multi-Immunotherapy Against Holistic Biofilm-Related Infections,” Advanced Materials 36, no. 11 (2024): e2308110.

[114] Y. Liang, J. He, X. Chen, et al., “The Emerging Roles of Metabolism in the Crosstalk Between Breast Cancer Cells and Tumor-Associated Macrophages,” International Journal of Biological Sciences 19, no. 15 (2023): 4915-4930.

[115] H. Yan, Z. Wang, D. Teng, et al., “Hexokinase 2 Senses Fructose in Tumor-Associated Macrophages to Promote Colorectal Cancer Growth,” Cell Metabolism 36, no. 11 (2024): 2449-2467.

[116] X. Zhang, Y. Fan, and K. Tan, “A Bird's Eye View of Mitochondrial Unfolded Protein Response in Cancer: Mechanisms, Progression and Further Applications,” Cell Death & Disease 15, no. 9 (2024): 667.

[117] J. Liu, B. Sun, K. Guo, et al., “Lipid-Related FABP5 Activation of Tumor-Associated Monocytes Fosters Immune Privilege via PD-L1 Expression on Treg Cells in Hepatocellular Carcinoma,” Cancer Gene Therapy 29, no. 12 (2022): 1951-1960.

[118] S. Zuo, Y. Wang, H. Bao, et al., “Lipid Synthesis, Triggered by PPARγ T166 Dephosphorylation, Sustains Reparative Function of Macrophages During Tissue Repair,” Nature Communications 15, no. 1 (2024): 7269.

[119] P. S. Liu, Y. T. Chen, X. Li, et al., “CD40 Signal Rewires Fatty Acid and Glutamine Metabolism for Stimulating Macrophage Anti-Tumorigenic Functions,” Nature Immunology 24, no. 3 (2023): 452-462.

[120] N. Shao, H. Qiu, J. Liu, et al., “Targeting Lipid Metabolism of Macrophages: A New Strategy for Tumor Therapy,” Journal of Advanced Research 68 (2025): 99-114.

[121] Y. Shen, S. Xu, C. Ye, et al., “Proteomic and Single-Cell Landscape Reveals Novel Pathogenic Mechanisms of HBV-Infected Intrahepatic Cholangiocarcinoma,” Iscience 26, no. 2 (2023): 106003.

[122] M. Chen, S. Zhao, X. Xie, et al., “Role of Tunneling Nanotubes in Arachidonic Acid Transfer and Macrophage Function Reprogramming in Intrahepatic Cholangiocarcinoma,” Advanced Sciences (Weinheim) (2025): e00148.

[123] S. M. Morrissey, F. Zhang, and C. Ding, “Tumor-Derived Exosomes Drive Immunosuppressive Macrophages in a Pre-Metastatic Niche Through Glycolytic Dominant Metabolic Reprogramming,” Cell Metabolism 33, no. 10 (2021): 2040-2058. e2010.

[124] M. A. Gonzalez, D. R. Lu, M. Yousefi, et al., “Phagocytosis Increases an Oxidative Metabolic and Immune Suppressive Signature in Tumor Macrophages,” Journal of Experimental Medicine 220, no. 6 (2023): e20221472.

[125] J. Wang, P. Yang, T. Yu, et al., “Lactylation of PKM2 Suppresses Inflammatory Metabolic Adaptation in Pro-Inflammatory Macrophages,” International Journal of Biological Sciences 18, no. 16 (2022): 6210-6225.

[126] X. M. Li, Y. Yang, F. Q. Jiang, et al., “Histone Lactylation Inhibits RARγ Expression in Macrophages to Promote Colorectal Tumorigenesis Through Activation of TRAF6‒IL-6‒STAT3 Signaling,” Cell Reports 43, no. 2 (2024): 113688.

[127] J. Y. Wu, T. W. Huang, Y. T. Hsieh, et al., “Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis Via Succinate Receptor,” Molecular Cell 77, no. 2 (2020): 213-227. e215.

[128] P. Yang, H. Qin, Y. Li, et al., “CD36-Mediated Metabolic Crosstalk Between Tumor Cells and Macrophages Affects Liver Metastasis,” Nature Communications 13, no. 1 (2022): 5782.

[129] M. J. Watson and G. M. Delgoffe, “Fighting in a Wasteland: Deleterious Metabolites and Antitumor Immunity,” Journal of Clinical Investigation 132, no. 2 (2022).

[130] S. Jiang, X. Wang, D. Song, et al., “Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR Through APMAP,” Cancer Research 79, no. 12 (2019): 3063-3075.

[131] P. Saha, P. Ettel, and T. Weichhart, “Leveraging Macrophage Metabolism for Anticancer Therapy: Opportunities and Pitfalls,” Trends in Pharmacological Sciences 45, no. 4 (2024): 335-349.

[132] J. Kzhyshkowska, J. Shen, and I. Larionova, “Targeting of TAMs: Can We be More Clever Than Cancer Cells?,” Cellular & Molecular Immunology 21, no. 12 (2024): 1376-1409.

[133] J. Wang, T. Yuan, B. Yang, et al., “SDH Defective Cancers: Molecular Mechanisms and Treatment Strategies,” Cell Biology and Toxicology 41, no. 1 (2025): 74.

[134] J. Zhang, H. Zhang, X. Ding, et al., “Crosstalk Between Macrophage-Derived PGE(2) and Tumor UHRF1 Drives Hepatocellular Carcinoma Progression,” Theranostics 12, no. 8 (2022): 3776-3793.

[135] M. B. Gayatri, R. K. Kancha, D. Patchva, et al., “Metformin Exerts Antileukemic Effects by Modulating Lactate Metabolism and Overcomes Imatinib Resistance in Chronic Myelogenous Leukemia,” FEBS Journal 290, no. 18 (2023): 4480-4495.

[136] T. Wang, Z. Ye, Z. Li, et al., “Lactate-Induced Protein Lactylation: A Bridge Between Epigenetics and Metabolic Reprogramming in Cancer,” Cell Proliferation 56, no. 10 (2023): e13478.

[137] Y. D. Zhao, H. W. An, and M. Mamuti, “Reprogramming Hypoxic Tumor-Associated Macrophages by Nanoglycoclusters for Boosted Cancer Immunotherapy,” Advanced Materials 35, no. 24 (2023): e2211332.

[138] P. Su, Q. Wang, E. Bi, et al., “Enhanced Lipid Accumulation and Metabolism are Required for the Differentiation and Activation of Tumor-Associated Macrophages,” Cancer Research 80, no. 7 (2020): 1438-1450.

[139] H. Wu, Y. Han, Y. Rodriguez Sillke, et al., “Lipid Droplet-Dependent Fatty Acid Metabolism Controls the Immune Suppressive Phenotype of Tumor-Associated Macrophages,” EMBO Molecular Medicine 11, no. 11 (2019): e10698.

[140] D. H. Kim, N. Y. Song, and H. Yim, “Targeting Dysregulated Lipid Metabolism in the Tumor Microenvironment,” Archives of Pharmacal Research 46, no. 11-12 (2023): 855-881.

[141] N. M. Chapman and H. Chi, “Metabolic Rewiring and Communication in Cancer Immunity,” Cell Chemical Biology 31, no. 5 (2024): 862-883.

[142] J. Su, Z. Zheng, C. Bian, et al., “Functions and Mechanisms of Lactylation in Carcinogenesis and Immunosuppression,” Frontiers in Immunology 14 (2023): 1253064.

[143] A. N. Chen, Y. Luo, Y. H. Yang, et al., “Lactylation, a Novel Metabolic Reprogramming Code: Current Status and Prospects,” Frontiers in Immunology 12 (2021): 688910.

[144] Y. Zhang, Q. Peng, J. Zheng, et al., “The Function and Mechanism of Lactate and Lactylation in Tumor Metabolism and Microenvironment,” Genes & Diseases 10, no. 5 (2023): 2029-2037.

[145] R. Qin, W. Ren, G. Ya, et al., “Role of Chemokines in the Crosstalk Between Tumor and Tumor-Associated Macrophages,” Clinical and Experimental Medicine 23, no. 5 (2023): 1359-1373.

[146] Q. Shi, Q. Shen, Y. Liu, et al., “Increased Glucose Metabolism in TAMs Fuels O-GlcNAcylation of Lysosomal Cathepsin B to Promote Cancer Metastasis and Chemoresistance,” Cancer Cell 40, no. 10 (2022): 1207-1222. e1210.

[147] S. Jiang, W. Li, J. Yang, et al., “Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma,” ACS Nano 18, no. 8 (2024): 6445-6462.

[148] Y. Yu, Y. Liang, F. Xie, et al., “Tumor-Associated Macrophage Enhances PD-L1-Mediated Immune Escape of Bladder Cancer Through PKM2 Dimer-STAT3 Complex Nuclear Translocation,” Cancer Letters 593 (2024): 216964.

[149] G. Peng, B. Li, H. Han, et al., “Extracellular PKM2 Modulates Cancer Immunity by Regulating Macrophage Polarity,” Cancer Immunology, Immunotherapy 74, no. 7 (2025): 195.

[150] M. Praharaj, F. Shen, A. J. Lee, et al., “Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers,” Cancer Immunology Research 12, no. 7 (2024): 854-875.

[151] D. Zhang, A. M. Li, G. Hu, et al., “PHGDH-Mediated Endothelial Metabolism Drives Glioblastoma Resistance to Chimeric Antigen Receptor T Cell Immunotherapy,” Cell Metabolism 35, no. 3 (2023): 517-534. e518.

[152] I. K. Mellinghoff, D. Van M. J. Bent, et al., “Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma,” New England Journal of Medicine 389, no. 7 (2023): 589-601.

[153] F. Guan, R. Wang, Z. Yi, et al., “Tissue Macrophages: Origin, Heterogenity, Biological Functions, Diseases and Therapeutic Targets,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 93.

[154] M. Molgora, Y. A. Liu, M. Colonna, et al., “TREM2: A New Player in the Tumor Microenvironment,” Seminars in Immunology 67 (2023): 101739.

[155] J. Encarnación-Rosado, A. S. W. Sohn, D. E. Biancur, et al., “Targeting Pancreatic Cancer Metabolic Dependencies Through Glutamine Antagonism,” Nature Cancer 5, no. 1 (2024): 85-99.

[156] R. Pillai and T. Papagiannakopoulous, “DON of Hope: Starving Pancreatic Cancer by Glutamine Antagonism,” Cancer Research 84, no. 3 (2024): 349-350.

[157] R. Rais, K. M. Lemberg, L. Tenora, et al., “Discovery of DRP-104, a Tumor-Targeted Metabolic Inhibitor Prodrug,” Science Advances 8, no. 46 (2022): eabq5925.

[158] C. Liu, Q. Yin, Z. Wu, et al., “Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities,” Journal of Inflammation Research 18 (2025): 895-909.

[159] H. Jin, Y. He, P. Zhao, et al., “Targeting Lipid Metabolism to Overcome EMT-Associated Drug Resistance via Integrin β3/FAK Pathway and Tumor-Associated Macrophage Repolarization Using Legumain-Activatable Delivery,” Theranostics 9, no. 1 (2019): 265-278.

[160] C. Oyarce, A. Vizcaino-Castro, S. Chen, et al., “Re-Polarization of Immunosuppressive Macrophages to Tumor-Cytotoxic Macrophages by Repurposed Metabolic Drugs,” Oncoimmunology 10, no. 1 (2021): 1898753.

[161] H. Wang, F. Franco, Y. C. Tsui, et al., “CD36-Mediated Metabolic Adaptation Supports Regulatory T Cell Survival and Function in Tumors,” Nature Immunology 21, no. 3 (2020): 298-308.

[162] Y. Dang, J. Yu, S. Zhao, et al., “GOLM1 Drives Colorectal Cancer Metastasis by Regulating Myeloid-Derived Suppressor Cells,” Journal of Cancer 12, no. 23 (2021): 7158-7166.

[163] S. Y. Zhang, X. Y. Song, Y. Li, et al., “Tumor-associated Macrophages: A Promising Target for a Cancer Immunotherapeutic Strategy,” Pharmacological Research 161 (2020): 105111.

[164] H. Liu, R. Deng, C. W. Zhu, et al., “Rosmarinic Acid in Combination With Ginsenoside Rg1 Suppresses Colon Cancer Metastasis via Co-Inhibition of COX-2 and PD1/PD-L1 Signaling Axis,” Acta Pharmacologica Sinica 45, no. 1 (2024): 193-208.

[165] B. Yu, Y. Wang, T. Bing, et al., “Platinum Prodrug Nanoparticles With COX-2 Inhibition Amplify Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer,” Advanced Materials 36, no. 11 (2024): e2310456.

[166] J. Zheng, J. Jiang, Y. Pu, et al., “Tumor-Associated Macrophages in Nanomaterial-Based Anti-Tumor Therapy: As Target Spots or Delivery Platforms,” Frontiers in Bioengineering and Biotechnology 11 (2023): 1248421.

[167] X. Kang, Y. Huang, H. Wang, et al., “Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy,” Pharmaceutics 16, no. 1 (2023): 61.

[168] Y. Zhou, J. Yuan, K. Xu, et al., “Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy,” ACS Nano 18, no. 3 (2024): 1846-1864.

[169] N. Zhang, J. Zhou, S. Li, et al., “Advances in Nanoplatforms for Immunotherapy Applications Targeting the Tumor Microenvironment,” Molecular Pharmaceutics 21, no. 2 (2024): 410-426.

[170] Z. Wei, X. Zhang, T. Yong, et al., “Boosting Anti-PD-1 Therapy With Metformin-Loaded Macrophage-Derived Microparticles,” Nature Communications 12, no. 1 (2021): 440.

[171] Y. K. Liu, M. Hao, and F. Yang, “Scavenger Receptors: An Auspicious Therapeutic Target for Autoimmune Diseases,” Clinical Immunology 279 (2025): 110546.

[172] L. M. Sly and D. M. McKay, “Macrophage Immunotherapy: Overcoming Impediments to Realize Promise,” Trends in Immunology 43, no. 12 (2022): 959-968.

[173] K. A. Reiss, M. G. Angelos, E. C. Dees, et al., “CAR-Macrophage Therapy for HER2-Overexpressing Advanced Solid Tumors: A Phase 1 Trial,” Nature Medicine 31, no. 4 (2025): 1171-1182.

[174] Y. Bordon, “Pro-Tumour Programming at the Macrophage Membrane,” Nature Reviews Immunology 19, no. 5 (2019): 270-271.

[175] K. C. Corn, M. A. Windham, and M. Rafat, “Lipids in the Tumor Microenvironment: From Cancer Progression to Treatment,” Progress in Lipid Research 80 (2020): 101055.

[176] F. Khan, L. Pang, M. Dunterman, et al., “Macrophages and Microglia in Glioblastoma: Heterogeneity, Plasticity, and Therapy,” Journal of Clinical Investigation 133, no. 1 (2023): e163446.

[177] S. Cheruku, V. Rao, R. Pandey, et al., “Tumor-Associated Macrophages Employ Immunoediting Mechanisms in Colorectal Tumor Progression: Current Research in Macrophage Repolarization Immunotherapy,” International Immunopharmacology 116 (2023): 109569.

[178] D. J. Kloosterman and L. Akkari, “Macrophages at the Interface of the Co-Evolving Cancer Ecosystem,” Cell 186, no. 8 (2023): 1627-1651.

[179] Y. Wu, X. Pu, X. Wang, et al., “Reprogramming of Lipid Metabolism in the Tumor Microenvironment: A Strategy for Tumor Immunotherapy,” Lipids in Health and Disease 23, no. 1 (2024): 35.

[180] G. Ma, H. Jia, Z. Li, et al., “Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by Long-Term Glutamine Blockade in Bladder Cancer,” Cancer Immunology Research 13, no. 1 (2025): 66-83.

[181] O. O. Yeku, M. Barve, W. W. Tan, et al., “Myeloid Targeting Antibodies PY159 and PY314 for Platinum-Resistant Ovarian Cancer,” Journal for ImmunoTherapy of Cancer 13, no. 3 (2025): e010959.

[182] M. Binnewies, J. L. Pollack, J. Rudolph, et al., “Targeting TREM2 on Tumor-Associated Macrophages Enhances Immunotherapy,” Cell Reports 37, no. 3 (2021): 109844.

[183] K. E. Beckermann, A. Patnaik, I. Winer, et al., “A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of py314 in Combination With Pembrolizumab in Patients With Advanced Renal Cell Carcinoma,” Investigational New Drugs 42, no. 2 (2024): 179-184.

[184] S. Takano, Y. Miyashima, S. Fujii, et al., “Molecular Bottlebrushes for Immunostimulatory CpG ODN Delivery: Relationship Among Cation Density, Complex Formation Ability, and Cytotoxicity,” Biomacromolecules 24, no. 3 (2023): 1299-1309.

[185] X. Zhang, Q. Hu, X. He, et al., “CD16 CAR-T Cells Enhance Antitumor Activity of CpG ODN-Loaded Nanoparticle-Adjuvanted Tumor Antigen-Derived Vaccine Via ADCC Approach,” Journal of Nanobiotechnology 21, no. 1 (2023): 159.

[186] B. Ma, Y. Ma, B. Deng, et al., “Tumor Microenvironment-Responsive Spherical Nucleic Acid Nanoparticles for Enhanced Chemo-Immunotherapy,” Journal of Nanobiotechnology 21, no. 1 (2023): 171.

[187] A. Diab, P. A. Ascierto, M. Maio, et al., “Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination with Ipilimumab Versus Ipilimumab Alone in Patients with Advanced Refractory Melanoma (ILLUMINATE-301),” Journal of Clinical Oncology 43, no. 15 (2025): 1800-1809.

[188] H. Jin, Y. He, P. Zhao, et al., “Targeting Lipid Metabolism to Overcome EMT-Associated Drug Resistance Via Integrin beta3/FAK Pathway and Tumor-Associated Macrophage Repolarization Using Legumain-Activatable Delivery,” Theranostics 9, no. 1 (2019): 265-278.

[189] I. Yofe, T. Shami, N. Cohen, et al., “Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary,” Cancer Discovery 13, no. 12 (2023): 2610-2631.

[190] M. Molgora, E. Esaulova, W. Vermi, et al., “TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy,” Cell 182, no. 4 (2020): 886-900. e817.

[191] B. Di Luccia, M. Molgora, D. Khantakova, et al., “TREM2 Deficiency Reprograms Intestinal Macrophages and Microbiota to Enhance anti-PD-1 Tumor Immunotherapy,” Science Immunology 9, no. 95 (2024): eadi5374.

[192] L. Xu, Y. Zhang, Z. Lin, et al., “FASN-Mediated Fatty Acid Biosynthesis Remodels Immune Environment in Clonorchis Sinensis Infection-Related Intrahepatic Cholangiocarcinoma,” Journal of Hepatology 81, no. 2 (2024): 265-277.

[193] B. Tang, J. Zhu, Y. Shi, et al., “Tumor Cell-Intrinsic MELK Enhanced CCL2-Dependent Immunosuppression to Exacerbate Hepatocarcinogenesis and Confer Resistance of HCC to Radiotherapy,” Molecular Cancer 23, no. 1 (2024): 137.

[194] Y. Li, J. Tang, J. Jiang, et al., “Metabolic Checkpoints and Novel Approaches for Immunotherapy Against Cancer,” International Journal of Cancer 150, no. 2 (2022): 195-207.

[195] X. Zhang, L. Ji, and M. O. Li, “Control of Tumor-Associated Macrophage Responses by Nutrient Acquisition and Metabolism,” Immunity 56, no. 1 (2023): 14-31.

[196] S. Malik, N. Sureka, S. Ahuja, et al., “Tumor-Associated Macrophages: A Sentinel of Innate Immune System in Tumor Microenvironment Gone Haywire,” Cell Biology International 48, no. 10 (2024): 1406-1449.

[197] M. Xiao and X. Li, “The Impact of the Tumor Microenvironment on Macrophages,” Frontiers in Immunology 16 (2025): 1572764.

[198] J. Cao and C. Liu, “Mechanistic Studies of Tumor-Associated Macrophage Immunotherapy,” Frontiers in Immunology 15 (2024): 1476565.

[199] H. Yang, C. Kim, and W. Zou, “Metabolism and Macrophages in the Tumor Microenvironment,” Current Opinion in Immunology 91 (2024): 102491.

[200] C. Liao, X. Liu, C. Zhang, et al., “Tumor Hypoxia: From Basic Knowledge to Therapeutic Implications,” Seminars in Cancer Biology 88 (2023): 172-186.

[201] R. A. Khouzam, B. Janji, J. Thiery, et al., “Hypoxia as a Potential Inducer of Immune Tolerance, Tumor Plasticity and a Driver of Tumor Mutational Burden: Impact on Cancer Immunotherapy,” Seminars in Cancer Biology 97 (2023): 104-123.

[202] Z. Chen, F. Han, Y. Du, et al., “Hypoxic Microenvironment in Cancer: Molecular Mechanisms and Therapeutic Interventions,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 70.

[203] Y. Mao, J. Zhang, Q. Zhou, et al., “Hypoxia Induces Mitochondrial Protein Lactylation to Limit Oxidative Phosphorylation,” Cell Research 34, no. 1 (2024): 13-30.

[204] G. M. Tannahill, A. M. Curtis, J. Adamik, et al., “Succinate is an Inflammatory Signal That Induces IL-1β Through HIF-1α,” Nature 496, no. 7444 (2013): 238-242.

[205] J. Li, Y. Ye, Z. Liu, et al., “Macrophage Mitochondrial Fission Improves Cancer Cell Phagocytosis Induced by Therapeutic Antibodies and is Impaired by Glutamine Competition,” Nature Cancer 3, no. 4 (2022): 453-470.

[206] Y. Zhai, X. Liang, and M. Deng, “Myeloid Cells Meet CD8(+) T Cell Exhaustion in Cancer: What, Why and How,” Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu 36, no. 6 (2024): 616-651.

[207] L. Liu, Y. Li, and B. Li, “Interactions Between Cancer Cells and Tumor-associated Macrophages in Tumor Microenvironment,” Biochimica Biophysica Acta: Reviews on Cancer 1880, no. 3 (2025): 189344.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.